Secondary hyperoxaluria: Cause and consequence of chronic kidney disease.

Laura Salanova, Borja Quiroga, Loreto Mariscal de Gante, Mariel Valdivia Mazeyra, Rosario Serrano Pardo

Journal: Nefrologia 2025;45(1):5-14

PMID: 39800598

Abstract

Secondary hyperoxaluria is a metabolic disorder characterized by an increase in urinary oxalate excretion. The etiology may arise from an increase in the intake of oxalate or its precursors, decreased elimination at the digestive level, or heightened renal excretion. Recently, the role of the SLC26A6 transporter in the etiopathogenesis of this disease has been identified. This transporter is active at both the intestinal and renal levels, and its mechanism of action is disrupted during systemic inflammation and metabolic syndrome, which could explain the rising incidence of secondary hyperoxaluria in recent decades. Treatment includes hygienic dietary measures, and medications aimed at reducing intestinal absorption by increasing fecal excretion. Different immunomodulatory drugs, microbiome modifiers and SGLT2 inhibitors could constitute new therapeutic targets. Currently, specific treatments for secondary hyperoxaluria are lacking, making early diagnosis and preventive measures against kidney failure the main therapeutic strategies.

Copyright © 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.

Address: Servicio de Nefrología, Hospital Universitario de la Princesa, Madrid, Spain.; Servicio de Anatomía Patológica, Hospital Universitario de la Princesa, Madrid, Spain.; Servicio de Nefrología, Hospital Universitario de la Princesa, Madrid, Spain. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.